Histidinate
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder.
Journal: Annals of medicine and surgery (2012)
Published: March 09, 2026
"A new era in Menkes disease management: the disease-modifying impact of Zycubo (copper histidinate)".
Journal: Annals of medicine and surgery (2012)
Published: February 25, 2026
Menkes Disease: Another Example of Progress in the Development of Pharmaceuticals for Rare Childhood Diseases, But Much Still Remains to Be Done.
Journal: Clinical therapeutics
Published: February 24, 2026
Zycubo (copper histidinate), the first treatment for pediatric Menkes disease.
Journal: Trends in pharmacological sciences
Published: January 28, 2026
CRISPR prime editing as a promising therapeutic avenue for Menkes disease: the next step in correcting ATP7A mutations.
Journal: Annals of medicine and surgery (2012)
Published: November 04, 2025
Overcoming barriers in Menkes disease: A standardized high quality and stable injectable copper histidinate.
Journal: Journal of pharmaceutical sciences
Published: October 02, 2024
Influence of Cu L-Histidinate Schiff Base Derivatives on Structural Features of Irradiated Rat's DNA.
Journal: Cell biochemistry and biophysics
Published: June 13, 2024
Switchable Double Inversion of Chirality in a Helical Polyelectrolyte.
Journal: ACS macro letters
Published: May 08, 2023
Newly identified disorder of copper metabolism caused by variants in CTR1, a high-affinity copper transporter.
Journal: Human molecular genetics
Published: April 11, 2022
Last Updated: 06/30/2026